Carcinoma, Non-Small Cell Lung Clinical Trials in Los Angeles, California
11 recruitingLos Angeles, California
Showing 1–11 of 11 trials
Recruiting
Phase 2
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC480 enrolled201 locationsNCT06667076
Recruiting
Phase 3
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled346 locationsNCT07222566
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled361 locationsNCT06890598
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled422 locationsNCT06119581
Recruiting
Phase 3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Carcinoma, Non-Small Cell Lung
Merck Sharp & Dohme LLC680 enrolled232 locationsNCT06623422
Recruiting
Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled159 locationsNCT04389632
Recruiting
Phase 2
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC300 enrolled93 locationsNCT06120140
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Esophageal CancerPancreatic CancerUrothelial Carcinoma+10 more
Pfizer310 enrolled28 locationsNCT07090499
Recruiting
Phase 1Phase 2
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Carcinoma, Non-Small Cell Lung
Genprex, Inc.158 enrolled10 locationsNCT04486833
Recruiting
Phase 3
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Carcinoma, Non-Small Cell Lung
AstraZeneca280 enrolled105 locationsNCT06008093
Recruiting
Phase 1Phase 2
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Carcinoma, Non-Small Cell LungOvarian NeoplasmsColorectal Neoplasms+3 more
Eli Lilly and Company540 enrolled49 locationsNCT04956640